IperionX validates GenX continuous titanium production. Validation of GenX continuous titanium production advances IperionX core manufacturing capability and competitive position.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | 4 | 2 | — | — | 2 | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2026 | ‡‡‡‡‡ |
|
| 2025 | ‡‡‡‡‡ |
|
| 2024 | ‡‡‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'25 | |
|---|---|---|---|---|
| Cash | 11.94 | 33.16 | 54.81 | 65.83 |
| Receivables | 0.23 | 2.30 | 0.82 | 1.15 |
| Inventory | — | 0.02 | — | 0.43 |
| Other | 0.59 | — | — | — |
| 12.75 | 41.55 | 58.88 | 69.57 |
| 2023 | 2024 | 2025 | Q'25 | |
|---|---|---|---|---|
| Payables | 1.18 | 2.32 | 7.49 | 10.37 |
| ST’ Debt | 0.38 | 0.45 | 0.47 | 1.11 |
| Other | 0.08 | 0.29 | 0.47 | 5.80 |
| 1.65 | 3.05 | 8.43 | 17.27 |
| 10y | 5y | 3y | |
| Sales | — | — | — |
| Cash Flow | — | ‡‡‡ | ‡‡‡ |
| Earnings | — | ‡‡‡ | ‡‡‡ |
| Book Value | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Year |
|---|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | (16.70) |
—
|
| ’25 | — | (21.80) | — | (11.75) |
(21.80)
|
| ’24 | — | (18.61) | — | (7.97) |
(18.61)
|
| ’23 | — | (15.86) | — | (7.59) |
(15.86)
|
| ’22 | — | (12.13) | — | (5.85) |
(12.13)
|
| ’21 | — | (3.56) | — | (0.55) |
(3.56)
|
| ’20 | — | — | — | — |
(0.45)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | (33.01) |
—
|
| ’25 | — | (39.40) | — | (22.73) |
(46.07)
|
| ’24 | — | (24.64) | — | (12.82) |
(24.64)
|
| ’23 | — | (18.57) | — | (9.19) |
(18.57)
|
| ’22 | — | (14.95) | — | (5.85) |
(14.95)
|
| ’21 | — | (4.13) | — | (0.55) |
(4.13)
|
| ’20 | — | — | — | — |
(0.45)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | — |
—
|
| ’25 | — | — | — | — |
(1.19)
|
| ’24 | — | — | — | — |
(1.00)
|
| ’23 | — | (0.05) | — | (0.06) |
(1.04)
|
| ’22 | — | (0.08) | — | (0.08) |
(1.60)
|
| ’21 | — | — | — | (0.05) |
(0.22)
|
| ’20 | — | — | — | — |
(0.01)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | 4.30 | 4.62 | 9.26 | 12.28 | — | — | — |
Low Price
|
| — | — | — | — | — | — | 8.44 | 18.57 | 38.93 | 60.90 | — | — | — |
High Price
|
| — | — | — | — | — | ‡‡‡‡ | 28 | 30 | 48 | 70 | — | — | — |
Employees
|
| — | — | — | — | — | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue/Emp
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue
|
| — | — | — | — | ‡‡‡ | ‡‡‡ | 0.00% | 0.00% | — | — | — | — | — |
Gross Margin
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (21.52) | (17.44) | (21.84) | (35.35) | — | — | — |
EBT
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | 0.00% | 0.00% | 0.00% | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (21.52) | (17.44) | (21.84) | (35.35) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.03 | 0.18 | 0.12 | 1.48 | — | — | — |
Depreciation
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.60) | (1.04) | (1.00) | (1.19) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Earnings/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.90) | (0.94) | (0.85) | (0.73) | ‡‡‡‡‡ | — | — |
Cash Flow/Sh
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | (0.21) | (0.16) | (0.28) | (0.82) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.11) | (1.11) | (1.13) | (1.55) | — | — | — |
Free CF/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.55 | 1.22 | 2.36 | 3.11 | ‡‡‡‡‡ | — | — |
Book Value/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 13.46 | 16.80 | 21.78 | 29.69 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ |
PE Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
EV/Sales
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
EV/FCF
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (12.13) | (15.86) | (18.61) | (21.80) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.82) | (2.71) | (6.03) | (24.28) | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Capex
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (14.95) | (18.57) | (24.64) | (46.07) | ‡‡‡‡‡ | — | — |
FCF
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 3.76 | 11.11 | 38.50 | 50.45 | — | — | — |
Working Cap'
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.54 | 0.98 | 1.49 | 3.93 | — | — | — |
Total Debt
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (5.13) | (10.96) | (31.67) | (50.88) | — | — | — |
Net Debt
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 7.42 | 20.56 | 51.34 | 92.44 | — | — | — |
Sh' Equity
|
| — | — | — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (338.91%) | (106.66%) | (55.84%) | (44.06%) | — | — | — |
ROA
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | (596.86%) | (114.98%) | (71.85%) | (59.05%) | — | — | — |
ROIC
|
| — | — | — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (468.88%) | (124.68%) | (60.76%) | (49.17%) | — | — | — |
ROE
|
IperionX Limited (IPX), via its Sponsored ADR, stands out as an Australian innovator disrupting titanium production with proprietary HAMR technology, delivering low-cost, sustainable output for booming sectors like aerospace, EVs, and defense amid global supply chain reshoring. Once a speculative explorer with negligible revenue and mounting losses from heavy R&D and capex—peaking at $24 million in 2025—the company has built a resilient balance sheet, securing U.S. DoD contracts, NASA ties, and Virginia plant funding. Its stock has mirrored this evolution, surging from $4 lows to $39 highs in 2024, with recent momentum reflecting breakout potential.
Analyst forecasts ignite the growth narrative: revenue exploding from zero to $17 million in 2025, $112 million in 2026 (+550%), and $345 million in 2027 (+209%), flipping net losses of -$35 million in 2025 to $16.8 million profit in 2027 and $186 million in 2028. EPS turns positive at +0.46 by 2027, with valuations compressing to attractive 11.8x P/E and 4.8x EV/Sales by 2028. Consensus price targets signal 42-81% upside, betting on HAMR’s edge over energy-intensive rivals, fueled by titanium price spikes from Ukraine sanctions and Western decoupling from China.
Yet caution prevails: persistent cash burn, massive share dilution to 338 million, zero insider trading, and execution risks could stall the rally if milestones slip. With ROIC improving and geopolitics aligning, IPX echoes high-reward innovator plays—but delivery is key. Dive into the full analysis for step-by-step fundamentals, price correlations, and 2027 inflection risks.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.